STAT3 and metabolic dysfunction-associated steatohepatitis: All these findings suggest that resmetirom might improve NAFLD/NASH by influencing the activation of the Toll-like receptor and Jak-STAT3 signaling pathways, as both of them have been proven to take part in regulating inflammation and contribute to the development of NASH [22,23].